Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

This study tests a CAR-T cell therapy — a form of personalized immune cell treatment — that targets the CD4 protein on leukemia cells in patients with acute myeloid leukemia (AML) that has not responded to standard treatment. **You may be eligible if...** - You are 12 years of age or older - You have been diagnosed with CD4-positive AML - Your leukemia has not responded to or came back after standard first-line treatment (such as induction chemotherapy or azacitidine plus venetoclax) - You are able to provide written consent **You may NOT be eligible if...** - Your AML does not have the CD4 protein on the cancer cells - You have not yet tried standard first-line treatment - You have severe other medical conditions that would make this therapy unsafe Talk to your doctor to see if this trial is right for you.